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Abstract
Thrombin is a serine proteinase that plays a fundamental role in coagulation. In this study, we address the effects of ligand
site recognition by alpha-thrombin on conformation and energetics in solution. Active site occupation induces large
changes in secondary structure content in thrombin as shown by circular dichroism. Thrombin-D-Phe-Pro-Arg-chloromethyl
ketone (PPACK) exhibits enhanced equilibrium and kinetic stability compared to free thrombin, whose difference is rooted
in the unfolding step. Small-angle X-ray scattering (SAXS) measurements in solution reveal an overall similarity in the
molecular envelope of thrombin and thrombin-PPACK, which differs from the crystal structure of thrombin. Molecular
dynamics simulations performed with thrombin lead to different conformations than the one observed in the crystal
structure. These data shed light on the diversity of thrombin conformers not previously observed in crystal structures with
distinguished catalytic and conformational behaviors, which might have direct implications on novel strategies to design
direct thrombin inhibitors.
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Introduction
Thrombin is a serine proteinase that plays a fundamental role in
several important physiological and pathological processes, such as
the coagulation, anticoagulation and fibrinolytic pathways, and is
therefore becoming an important target for drug design.
Alpha-thrombin (aTh) is composed of two disulfide-linked chains,
L (‘‘light’’) and H (‘‘heavy’’), with the catalytic site located in chain
H. Understanding the molecular basis of ligand recognition at the
active site is key for developing new compounds as candidates for
drugs that aim to intervene in coagulation.
T h ec r y s t a ls t r u c t u r eo faTh was elucidated more than 20 years ago
[1]; since then more than 300 crystal structures have been reported so
far, including complexes with various ligands, structures solved under
varying chemical conditions such as pH, precipitants and coadjuvants,
mutants designed to abrogate the autoproteolytic degradation [2,3]
and the wild-type recombinant human aTh in the absence of Na
+ ions
[4]. From this large database, no large conformational changes are
observed [5]. Only limited overall changes with global deviations on
the order of about 1 A ˚ and some limited local shifts in loops of small
secondary structure elements are seen. Despite the wealth of structures
available to date, there is no consolidated structural study in solution of
wild-type human aTh in the absence of inhibitors.
aTh can be reversibly unfolded by guanidine hydrochloride
(GdmCl), urea and high hydrostatic pressure, with disruption of its
catalytic site [6–8]. However, both the thermodynamics and
structural consequences of ligand binding to the active site remain
elusive. In the present work, we performed a comparative analysis
between aTh in the free form and in the bound state in solution.
To address this issue we used D-Phe-Pro-Arg-chloromethyl ketone
(PPACK), a selective aTh inhibitor [9], which has long been used
as a template in designing drugs that target aTh [5]. We have
combined small-angle X-ray scattering, molecular dynamics
simulations and equilibrium and kinetic folding thermodynamic
measurements to dissect the energetics and molecular features of
aTh and aTh-PPACK. Evidence for dynamic and conformational
changes between these forms is provided here, as well as the
mapping of a conformer in the equilibrium and kinetic folding
pathway, which correlates with increased aTh activity.
Materials and Methods
Material
Distilled water was deionized to less then 1.0 mS and filtered
through a 0.22 mm-pore membrane in a water purification system
prior to use. Hen egg white lysozyme (HEWL) and bovine serum
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Co, Saint Louis, Il). S-2238 was obtained from Chromogenix
(Mo ¨lndal, Sweden); D-Phe-Pro-Arg-cloromethylketone (PPACK)
was purchased from Calbiochem. Human aTh was purified as
previously described [10]. Protein concentration was determined
by UV absorbance at 280 nm [11,12]. Guanidine hydrochloride
(GdmCl) stock solutions were prepared immediately before use,
and the concentration was verified as described previously [13,14].
All other reagents were of analytical grade. All buffers and
solutions were prepared immediately prior use.
Small angle X-ray scattering
Small-angle X-ray scattering (SAXS) experiments were carried
out at the SAS1 and SAS2 beam lines [15] at the LNLS (National
Synchrotron Light Laboratory, Campinas, SP, Brazil), with either
50 or 100 mM aTh in either the free or inhibited form (1.2 molar
excess of PPACK). All samples were prepared in 20 mM
Tris.HCl, 100 mM NaCl, 15 mM EGTA, 10 mM MES, pH 6.0
at 25uC, centrifuged for 15 min at 15,000 g at 4uC and
maintained on ice until data collection. No proteolysis was
observed as judged by SDS-PAGE after SAXS measurements
(data not shown). Monodispersity was confirmed by dynamic light
scattering measurements (not shown).
SAXS data were performed in duplicate with equivalent
results using a one-dimensional position-sensitive detector (PSD
1D Hecus; SAS1 beamline) and a bidimensional detector
(MarCCD345) at the SAS2 beamline, on different occasions.
The wavelength (l) was set at 1.488 A ˚; the sample-detector
distance was set to provide a useful q-range from 0.02 A ˚ 21 to
0.30 A ˚ 21, calculated according to the following equation:
Ds~
100(R{1{R{1
0 )
R{1
0
q~
4p
l

sinh
ð1Þ
where q is the modulus of the scattering vector, and 2h is the
scattering angle. The scattering curves of the protein solutions and
buffers were collected in several successive frames of 900 s each to
monitorforradiation-inducedproteinoxidation.Thedata-reduction
routine included normalization of the one-dimension scattered data
to the intensity of the transmitted incident beam, correction for the
detector response, incident beam intensity, sample absorption, and
blank and detector background subtraction. Measurements were
performed using at least three different protein batches.
Guinier analysis [16] was applied to further evaluate mono-
dispersity of the samples and to determine the radius of gyration
(Rg)o faTh and aTh-PPACK. The Rg and the scattered intensity,
I0(q), were inferred, respectively, from the slope and the intercept
of the linear fit of ln[I(q)] versus q
2 in the q-range q*Rg,1.3 [16].
The same parameter was also obtained from the data fit of the
merged curve by the indirect Fourier transform program Gnom
[17,18], which also evaluates the distance-distribution function,
p(r). The maximum dimension, Dmax, was estimated from the dis-
tance distribution function p(r), with the limiting distance r where
p(r) first converges down to zero. The lack of the dependence of
the structural parameters obtained by SAXS on the protein
concentration indicates the absence of protein interactions at
this concentration range. The oligomeric states of aTh and
aTh-PPACK in SAXS measurements was confirmed from the
extrapolated values of scattering intensity at zero scattering
angle (I0) and normalized by sample concentration C according
to I0/C using BSA and HEWL as reference standards [19–21].
The SAXS data were analyzed by fitting the theoretical scattering
intensities computed from the crystal structure of PPACK-bound
aTh (PDB ID 1PPB) using Crysol [22], taking into account the
influence of the hydration shell. Similar results were obtained for
measurements performed either at 50 aM or 100 mMo faTh and
aTh-PPACK.
Equilibrium unfolding and refolding
Equilibrium unfolding was performed by incubating 500 nM
aTh or aTh-PPACK in the indicated GdmCl concentration and
allowing the reaction to equilibrate for at least 60 min, which is
sufficient time to achieve equilibrium [8]. Reversibility experi-
ments were performed by incubating aTh or aTh-PPACK at
20 mM in 4.5 M GdmCl, diluting it to 500 nM supplemented with
the necessary amount of GdmCl to achieve the indicated
concentration, and measuring fluorescence emission. Fluorescence
measurements were performed separately with three protein
batches in three spectrofluorimeters, a Jasco FP-6300 (Jasco Inc,
USA) and two Cary Eclipse (Varian Inc), with excitation set to
280 nm and emission scanned from 300 to 420 nm at a scanning
rate of 100 nm/min and response 8 seconds, datapitch 0.5 nm
and excitation and emission slits 2.5 nm. Fluorescence spectra
were quantified by the center of spectral mass ,v. according to
Eq [2]):
vvobsw~
S(liFi)
SFi
ð2Þ
where Fi is the fluorescence emitted at wavelength li and the
summation is carried out over the range cited above. All
experiments were performed at 25uC in PBS buffer (150 mM
NaCl, 3 mM KCl, 2 mM KH2PO4,1 0m MN a 2HPO4, pH 7.4).
Because aTh unfolding is fully reversible with no detectable
hysteresis [6,8], the transition between the native (N) and
denatured (D) conformational states can be defined by an
equilibrium denaturation constant, kden, as:
kden~
½D 
½N 
ð3Þ
and the free energy of unfolding can be calculated from
DGden~{RT lnkden ð4Þ
where R and T are respectively the universal gas constant
(1.9872 cal.mol
21.K
21) and temperature (in Kelvin).
The unfolding energy can generally be accessed from the
dependence of the monitoring signal (in this case, spectral center of
mass of intrinsic fluorescence emission) on the denaturant
concentration, by using the linear extrapolation method [23,24]
DGGdmCl~DG0{m½GdmCl ð 5Þ
where DGGdmCl is the free energy of unfolding at each respective
GdmCl concentration, DG
o is the standard unfolding free energy
(in this case, in the absence of denaturant) and m is a parameter
directly related to the difference in accessible surface area
(ASA) between the folded and unfolded states [25]. Combination
of Eq [4] and Eq [5] gives:
Kden~exp
{DG0zm½GdmCl 
RT

ð6Þ
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vvobsw~vvNwfNzvvDwfD ð7Þ
and
fNzfD~1 ð8Þ
where fN and fD are the fractional amount of protein in the native
and denatured states, respectively, it follows that
vvobsw~vvNw{(vvNw{vvDw)fD ð9Þ
where obs, N and D represent observed (i.e., at each corresponding
GdmCl concentration), native and denatured. The fraction of
denatured protein can be described as
fD~
½D 
½N z½D 
ð10Þ
Combination of Eq 3 and 10 gives
fD~
kden
1zkden
ð11Þ
and combining Eq [6], Eq [7] and Eq [10] results in
vvobsw~vvNw{(vvNw{vvDw)
exp((m½GdmCl {DG0)RT)
1zexp((m½GdmCl {DG0)RT)
 ð12Þ
which was used to fit the GdmCl-induced denaturation isotherms.
Thermal denaturation
Experiments were performed with aTh or aTh-PPACK in PBS
buffer, using both a Jasco J-715 (Jasco Corporation, Tokyo, Japan)
and a Chirascan (Applied Photophysics, UK) spectropolarimeter.
Heat denaturation curves were generated by monitoring the
ellipticity at 222 nm. Similar transitions were obtained with a
heating rate of 1 or 2uC/min, varying protein concentration and
cell path length, with equivalent mean transition temperature.
Temperature was varied by a Peltier controller. All experiments
were performed in triplicate, with three protein batches. Unfolding
curves were fit to a four-parameter sigmoid logistic function to
estimate the mean transition temperature of thermal denaturation.
Kinetic measurements
Kinetic unfolding experiments were performed using a SX18MV
stopped-flow apparatus (Applied Photophysics, UK). All exper-
iments were performed in PBS, at 25uC60.2uC (unless
otherwise stated), using syringes of different sizes for a 1:10
mixture and final protein concentration of 900 nM. Intrinsic
fluorescence was followed by setting the excitation wavelength to
280 nm, and monitoring the emission through a cut-off filter
(WG320, with 50% transmitance at 320 nm). All data presented
are an average of at least four runs, and the reported GdmCl
concentrations are the final values under measurement. Data
were adjusted to obtain the rates using non-linear least squares
fitting as provided by the manufacturer, with a single expo-
nential decay function. Kinetic refolding experiments were
performed by incubating aTh or aTh-PPACK with the desired
GdmCl concentration for at least 1 h and diluting the reaction
10 times with buffer and varying the amounts of GdmCl to
provide the indicated final concentration of GdmCl.
Molecular dynamic simulations
The MD simulations were performed with the aTh-PPACK
complex and free aTh based on the protein structure under PDB
entry 1PPB [1]. The GROMACS simulations suite [26] and
GROMOS96 force field [27] were used, employing an MD
protocol based on previous studies [28,29]. The architecture of
aTh-PPACK linking was made using charges, bonds, angles and
dihedrals parameters founded in GROMOS96 43a1 force field.
The final complex is a hemiketal tetrahedrical structure binding
Ser195 and His57 side chains of the enzyme to Arg3 carbonyl
carbon of the PPACK. Both aTh and the aTh-PPACK complex
were solvated in rectangular boxes using a SPC water model [30]
by a layer of at least 9 A ˚ from the solute atoms. Counter ions (Cl
2)
were added to neutralize the system charges. The Lincs method
[31] was applied to constrain covalent bond lengths, allowing an
integration step of 2 fs after an initial energy minimization using
steepest descents algorithm under periodic boundary conditions.
The systems obtained, composed of aTh–solvent–ions and aTh–
PPACK-solvent–ions were heated slowly from 10 to 343 Kelvin, in
steps of 5 ps, in which the reference temperature was increased by
50 K. Both systems were kept at a temperature of 343 K for the
rest of the trajectory. Temperature and pressure were kept
constant by coupling protein, PPACK, ions, and solvent to
external temperature and pressure baths with coupling constants
of t=0.1 and 0.5 ps [32], respectively. No restraints were applied
after the thermalization phase. The electrostatic interactions were
evaluated by the particle–mesh Ewald method [33] with a charge
grid spacing of 1.2 A ˚, while Coulomb and Lennard–Jones
interactions were evaluated using a 9.0 A ˚ atom-based cutoff
[34]. The analyses were performed in all trajectory length, with
average values of interaction energies calculated in the last 20 ns of
the simulations, which last for a total of 50 ns including all
previous steps. Throughout the text we use the sequence
nomenclature as described elsewhere [1].
Results
Small-angle X-ray scattering
Ligand interaction with proteins might result in more complex
structural changes beyond local interaction. To characterize the
overall structural parameters that could be affected upon ligand
binding to aTh, we performed small-angle X-ray scattering
(SAXS). SAXS can assist the evaluation of structural patterns of
proteins such as protein oligomerization and structural remodel-
ing, and allow for a comparative analysis between the crystal and
solution structure of a protein [35].
The X-ray scattering patterns of aTh and aTh-PPACK are
very similar (Fig. 1A), with no detectable changes within the
resolution limits (Fig. 1A). A Guinier analysis of SAXS data [16]
provides the radius of gyration, which is similar for both aTh and
aTh-PPACK, of about 23 A ˚ (Fig. 1B; Table 1). The protein
globularity is evidenced by a Kratky plot [16,36], which also
reveals that both aTh forms display no flexible and/or unfolded
domains, as indicated by the typical hyperbolic distribution
(Fig. 1C). Pair distribution analysis shows behavior typical of
a globular protein for both aTh and aT-PPACK, confirming the
similarity in radius of gyration (Rg of about 23 A ˚) and maximum
distance Dmax (72 A ˚) (Fig. 1D; Table 1).
We also performed a comparative analysis of scattering
data in solution for aTh and aTh-PPACK with the existing
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curves from the crystal structure of aTh-PPACK (PDB entry 1PPB)
(Fig. 1, solid lines). The comparison between these simulated SAXS
curves and the experimental data resulted in discrepancy values (x
2)
of about 1.5 for both aTh and aTh-PPACK (Table 1), suggesting
that the overall shapes of both aTh and aTh-PPACK are not
similar to that from the crystal structure. Collectively, these data
indicate that binding to PPACK does not change both the overall
particle form and the molecular envelope of aTh, and that both
forms have a similar overall shape in solution, which is different
from that observed in thrombin crystal structures.
Conformational changes induced by active-site
occupation
To gain more insight on the structural changes in aTh upon ligand
binding to the active site, we monitored the changes in secondary
structure by circular dichroism (CD). The CD spectrum of aTh is
characteristic of an alpha-helix rich protein (Fig. 2A) in the far-UV
region, with minima at about 222 and 212 nm. Upon binding to
PPACK, the overall pattern of the aTh CD spectrum remains similar;
however, a decrease in molar ellipticity takes place, indicating some
degree ofsecondarystructure rearrangements.Changes in ellipticity in
the far-UV spectral region can also arise from perturbations near
aromatic residues in the active site, thought the contribution from
these effects is less than one order of magnitude of the protein molar
ellipticity [37]. These data indicate a complex behavior of the
secondary structural elements of aTh upon ligand binding.
Thermal unfolding
To gain insight on the overall energetic contributions of
PPACK binding to aTh, we used CD to monitor heat-induced
denaturation of aTh by monitoring the ellipticity at 222 nm. We
observed a steep decrease in ellipticity corresponding to protein
unfolding transitions at 58uC and 74uC for aTh and PPACK-
bound aTh, respectively (Fig. 2B). This change in thermal stability
is consistent with previously-reported stabilization of bovine
thrombin by PPACK [38]. The increase in stability is more likely
to derive from changes in protein conformation and dynamics
upon ligand binding than from its covalent linkage to thrombin or
the local energetics of ligand interaction at the active site.
Figure 1. Small-angle X-ray scattering analysis of aTh and aT-PPACK. SAXS measurements of free (closed circles) and active site-bound
(open symbols) aTh (A) Experimental scattering curves of aTh and aTh-PPACK; solid lines correspond to fits to data with the crystal structure of
aTh-PPACK (1PPB) using Crysol. Inset: linear q scale. (B) Guinier plot of the scattering function; solid lines correspond to first-order linear regression of
the data. The linearity of the Guinier plot indicated that both samples are monodispersed and constitute a unique species; (C) Kratky plot from raw
data and fitting from panel (A); (D) Distance distribution functions. Details in the Experimental Methods section.
doi:10.1371/journal.pone.0024735.g001
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both aTh forms, no quantitative thermodynamic parameters could
be estimated except for the apparent temperature of transition.
Equilibrium refolding and unfolding transition
To further evaluate the effects of active site occupation on aTh
overall stability and to estimate the energetic contribution of
binding, we performed equilibrium denaturation isotherms using
GdmCl as a denaturant and by monitoring changes in intrinsic
fluorescence of aTh [8]. The emission spectra of both aTh
forms progressively shifted to higher wavelengths, indicating
the exposure of aromatic amino acids to the bulk solvent as
a consequence of the unfolding process (Fig. 3A). A plot of the
spectral center of mass as a function of denaturant concentration
shows a sigmoid, cooperative transition with well-defined plateaus
at low and high GdmCl concentration (Fig. 3B). From these data,
we observe that PPACK binding to aTh induces a shift of the
curve to higher denaturant concentrations, indicating an increase
in protein stability (Fig. 3B).
The unfolding transition of both aTh and aTh-PPACK is
completely reversible without hysteresis [6,8]. The analysis of the
changes in fluorescence intensity as a function of denaturant
concentration shows an increase of about 25% for aTh-PPACK at
low denaturant concentrations (below 1 M GdmCl; Fig. 3C). Such
spectroscopic evidence suggests the existence of a well-populated
intermediate state between the folded and unfolded states of
Table 1. Structural and thermodynamic parameters of aTh and aTh-PPACK.
Structural Parameters
1 aTh aTh -PPACK
I(0) 0.150 0.147
Rg,A ˚ (Guinier) 23.4 (r
2=0.978) 21.9 (r
2=0.974)
Rg,A ˚ (real space; Gnom) 23.1160.149 22.5060.190
Rg,A ˚ (1PPB, Crysol) 23.3 21.9
Dmax,A ˚ (Gnom)7 2 627 2 62
Discrepancy value x
2 (Crysol; 1PPB.pdb) 1.67 1.54
Resolution (A ˚)
2 31 31
Thermodynamic Parameters
DG
0, kcal/mol
3 3.6860.26 15.3360.88
m, kcal/mol.M
3 3.1260.21 4.9660.28
Tm, uC
4 5860.2 7460.1
DH
{, kcal/mol
5 20.060.9 23.161.6
DS
{, kcal/mol.K
5 0.07160.001 0.07160.005
DCp
{, kcal/mol.K
5 (reference temperature=298 K) 0.6260.20 1.0060.42
1) from SAXS measurements;
2) Resolution is calculated as 2p/qmax;
3) from equilibrium GdmCl induced denaturation;
4) from heat induced denaturation, with equivalent results for both 1 and 2uC/min heating rate;
5) from kinetic measurements.
doi:10.1371/journal.pone.0024735.t001
Figure 2. Secondary structure effects of aTh active site occupation. (A) CD spectra of free (continuous line) and PPACK-bound (dashed line)
aTh. Spectra were collected at 30 mM for both proteins in 0.10 mm pathlength quartz cells. (B) Thermal unfolding of free (closed symbols) and
PPACK-bound (open symbols) aTh monitored by changes in ellipticity at 222 nm throughout the process. Solid lines are linear regression. Details in
the Experimental Methods section.
doi:10.1371/journal.pone.0024735.g002
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functional assays [8]. This behavior is not observed in the aTh
denaturation isotherm monitored both by the spectral center of
mass and fluorescence intensity, indicating either that this
intermediate state does not exist during equilibrium unfolding or
that it is spectroscopically silent.
Considering a reversible equilibrium system, we were able to
estimate the free energy (DG
0) of the transition between intermediate
and unfolded species. Adjusting Eq [12] to data gives provides a DG
0of
3.760.3 kcal/mol for apo aTh, in excellent agreement with the
unfolding DG
0of 3.460.3 kcal/mol obtained from our group by using
urea as denaturant [8]. Adjusting Eq [12] to data provides a DG
0 of
15.360.9 kcal/mol for aTh-PPACK. The difference between these
values (DDG
0
apo-PPACK) is the overall gain in unfolding free energy of
aTh-PPACK compared to the free enzyme, which is 11.6 kcal/mol,
about 3 times the free energy of unfolding for apo aTh.
From these denaturation curves we could also obtain the
m parameter, which is directly correlated to the difference in
solvent accessible surface area (DASA) between the folded (ASA
F)
and unfolded (ASA
U) states [25], as follow:
DASA~ASAU{ASAF ð13Þ
The m parameter also increased upon active site occupation,
changing from 3.1260.21 to 4.9660.3 for aTh and aTh-PPACK,
respectively, resulting in Dm=1.8. If PPACK binding to aTh leads
to changes in solvent accessibility and thus, in conformation, we
can assume that
DDASAbinding~DASAaTh{PPACK{DASAaTh
~(ASAU
aTh{PPACK{ASAF
aTh{PPACK)
{(ASAU
aTh{ASAF
aTh)
ð14Þ
Assuming that the final unfoldedstates foraTh and aTh-PPACK
are similar, with equivalent ASAU(ASAU
aTh~ASAU
aTh{PPACK),i t
follows that
DDASAbinding~ASAF
aTh{ASAF
aTh{PPACK ð15Þ
According to the GdmCl-induced unfolding curves (Fig. 2),
Dm is positive; therefore, DDASAbinding would also be positive.
This analysis allows us to suggest that folded aTh-PPACK has an
overall conformation that is slightly less solvated and thus slightly
more compact than folded, free aTh.
Kinetic refolding and unfolding transition
To address the kinetic basis for the thermodynamic stabilization
of aTh by PPACK and investigate the origins of the intermediate
species, we performed fast-kinetic unfolding and refolding
experiments using a stopped-flow setup by monitoring conforma-
tional changes via intrinsic fluorescence.
Mixing aTh or aTh-PPACK with GdmCl at varying
denaturant concentration lead to a decrease in fluorescence
intensity (Fig. 4A). No further changes are observed after 10 min
(data not shown). The kinetic traces for both aTh and aTh-
PPACK GdmCl-induced denaturation were fit to a single
exponential function according to the following equation:
Fobs~F0zAmp e{kt ð16Þ
where Fobs is the fluorescence signal measured at time t; Amp is
total fluorescence change from F0, the initial fluorescence signal,
and k is the rate constant for the observed transition. The data fit
well to this equation, as indicated by the residuals (Fig. 4C). An
apparent first-order kinetic event for both aTh and aTh-PPACK
unfolding transitions was observed, which may indicate a simple
two-state transition from folded to unfolded aTh or a multi-step
process with spectroscopically silent species.
In contrast, the refolding reaction of aTh and aTh-PPACK
shows a more complex behavior. The kinetic refolding for both
aTh and aTh-PPACK was performed by incubating them at high
GdmCl concentration and diluting back with buffer supplemented
with sufficient GdmCl to provide the final desired concentration.
Figure 3. Stability effects of aTh active site occupation. Evaluation of PPACK binding to aTh was probed by equilibrium denaturation induced
by GdmCl and monitored by intrinsic fluorescence spectroscopy. (A) Fluorescence spectra of free and PPACK-bound aTh in the presence and absence
of 4 M GdmCl. (B) Denaturation curve of free (closed circles) and PPACK-bound (open circles) aTh was monitored by changes in the spectral center of
mass. Solid lines are non-linear regression fitting with Eq [12]. (C) Changes in intrinsic fluorescence emission of free (closed circles) and PPACK-bound
(open circles) aTh as a function of GdmCl concentration. Note the increase in fluorescence emission in a pre-transition region for aTh-PPACK,
corresponding to the transition between the initial ‘native’ and the intermediate states. Excitation was set at 280 nm and emission scanned from
300 to 420 nm; both the spectral center of mass and spectral area were calculated. Details in the Experimental Methods section.
doi:10.1371/journal.pone.0024735.g003
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fluorescence intensity of both aTh and aTh-PPACK which is
preceded by a lag phase. These data indicate that at least two
events are taking place in the course of the refolding reaction. The
duration of the lag phase in the refolding kinetics is dependent on
GdmCl concentration (Fig. 4F), and linear extrapolation provides
a life-time of about 100 sec, corresponding to an apparent decay
rate constant, kUI of 0.001 sec
21, for the transition from the
unfolded state to an intermediate state ‘‘I’’ which is similar for both
aTh and aTh-PPACK.
The second transition in the refolding reaction can also fit well
to a simple first-order kinetic function (Eq. [16]; Fig. 4B and 4D).
From the analysis of the second transition in the refolding reaction,
we obtain an apparent refolding kinetic rate constant kIN , which
corresponds to the transition from the intermediate state ‘‘I’’ to the
native folded ‘‘N’’ conformation. A plot of the observed kinetic
constant versus the denaturant concentration is called a Chevron plot
[39]. The linear extrapolation of the observed kinetic constant to
zero concentration of GdmCl provides the kUN and kNU. For
thrombin (Fig. 4E), the apparent rate constant of refolding, kUN,
Figure 4. Kinetic measurements of GdmCl induced folding and unfolding transitions of aTh and aTh -PPACK. Kinetic traces (A and C)
and residuals (B and D) of unfolding (A; B) and refolding (C;D) transitions of aTh (closed circles) and aTh-PPACK (open circles). The curves were fit with
a single exponential decay, and the rate constant was calculated. Fitting residuals are shown for aTh (closed circles) and aTh-PPACK (open circles);
(E) Chevron plot – GdmCl dependence of the apparent rate constant of folding and unfolding of aTh and aTh-PPACK. The lack of linearity in the
Chevron plot indicates a kinetic mechanism more complex than a simple two-state model, and thus limits a precise quantitative analysis of the kinetic
process. (F) The dependence of the refolding lag phase as a function of GdmCl. (G) Temperature dependence on the kinetics of GdmCl-induced
unfolding of aTh and aTh-PPACK by jumping the GdmCl concentration from 0 to 4 M and monitoring by the changes in fluorescence intensity, as in
Fig. 4A. Lines represent the best fit with Eq 22. Details in the Experimental Methods section.
doi:10.1371/journal.pone.0024735.g004
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aTh) and aTh-
PPACK (kUN
aTh-PPACK).
Collectively, these data suggest that the mechanism of kinetic
refolding is similar for aTh and aTh-PPACK, as indicated by
a similar two-steps refolding. This implies that the basis for the
energetic stabilization of aTh upon ligand binding is mainly
determined by the kinetic unfolding pathway. Assuming that the
unfolded states of aTh and aTh-PPACK are similar, it is
suggestive to propose that the thermodynamic difference between
aTh and aTh-PPACK relies on the native conformation and/or
the activated state in the kinetic unfolding process.
In a perfect two-state conformational transition, the reference
native state of a protein is a result of the balance between the
refolding and unfolding kinetic constants:
N
kUN
L J
kNU
U ð17Þ
where kUF and kFU are the microscopic rates of the refolding and
denaturation reaction, respectively, and are related to the equilib-
rium denaturation constant keq according to the following [39,40]:
Keq~
kUN
kNU
ð18Þ
The dependence of the unfolding rate constants on GdmCl
concentration deviate from linearity for aTh at concentrations
higher than 2 M GdmCl (Fig. 4E). This rollover indicates that the
unfolding reaction is not a simple two-step reaction, and that at
least one intermediate is populated. This behavior is not observed
for aTh-PPACK at the GdmCl concentrations used. Instead,
a linear dependence on GdmCl concentration is observed.
However, we can not rule out the existence of a denaturation
intermediate for aTh-PPACK because we were not able to
achieve a GdmCl concentration higher than 5 M due to
limitations in the mixing procedure and the limited solubility of
reagents in the stock solution. Moreover, the refolding kinetic
process for both aTh and aTh-PPACK reveals two marked steps,
which is direct evidence for a process involving at least three
species: unfolded, intermediate and folded aTh. Therefore, based
on this evidence, we may assume the existence of at least one
refolding species named ‘‘I’’, such that:
N L J I L J U ð19Þ
The linear dependence of the kinetic rate constant on the
GdmCl concentration can be expressed by
DG
{
GdmCl~DG0{{m{½GdmCl ð 20Þ
where
{ denotes the transition or activated state. From the kinetic
refolding measurements, we observe a large dependence on kUI,
the microscopic rates of the U to I transition reaction, on GdmCl
concentration for both aTh and aTh-PPACK (Fig. 4F) and almost
no dependence on kIN, the microscopic kinetic rates of the I to N
transition reaction, on GdmCl concentration (Fig. 4E, between
0 and 1.5 M GdmCl). These data indicate that m
{
UI is positive and
m
{
IN is close to zero. As previously mentioned, the m paramenter
directly correlates to changes in solvent accessible surface area
(DASA) between the conformers involved in the transition [25].
From this analysis, we suggest that for both aTh and aTh-PPACK
the transition from aThUnf to aThInt involves change in hydration
and subsequently in solvent exclusion from the surface due to
protein condensation and that the transition from aThInt to
aThNative is accompanied by only minor changes in the solvent
accessible surface area. Moreover, these data suggest that the
kinetic intermediate state in the refolding and unfolding pathway
for both aTh and aTh-PPACK is equivalent to the refolding/
unfolding intermediate accumulated in equilibrium, and is more
closely related to the folded aTh than to unfolded aTh.
The current data clearly indicate the existence of a kinetic
intermediate in the unfolding/refolding pathways for both aTh
and aTh-PPACK. These data corroborate previous equilibrium
measurements from our group [8]. Unfortunately, it is still not
possible to confidently assign the number of refolding intermedi-
ates states or to know if each refolding intermediate is be the same
in both the unfolding and refolding pathways. Instead, our data
provide clear evidence for local energetic minima in the refolding
pathways for both aTh and aTh-PPACK, demonstrating the
diverse refolding trajectory of this enzyme.
Activation energy for refolding kinetics
To further understand the unfolding energetic of free and
PPACK-bound aTh, we performed a comparative analysis of the
kinetic energetic of apo and holo aTh unfolding by measuring the
thermal dependence of the denaturation kinetics of apo and holo
aTh at a fixed concentration of denaturant (4 M GdmCl) by
stopped-flow measurements. From the Arrhenius, it follows that
kobs~cexp
{DE{
RT

ð21Þ
where c is a pre-exponential coefficient, T is the temperature in
Kelvin, and DE
{ is the activation energy. The plot of ln k versus
1/RT is a linear function from which the angular coefficient
corresponds to DE
{. A deviation from linearity indicates that the
activation energy is dependent on temperature, and this
dependence is denoted as DCp
{, the change in activation heat
capacity [39,39–42].
If DCp
{ contributes to the underlying process, the process can
be better described according to the following:
Rlnkobs~
{DH{
T
zDS{{DCp{ 1{
T0
T
{ln
T
T0

ð22Þ
where DH
{ and DS
{ are the enthalpy and entropy activation
changes at the reference temperature T0, respectively.
From 5 to 30uC, the dependence of the apparent rate constant
on temperature in the form of logk versus 1/T (K
21) is slightly
non-linear (Fig. 4G). Using Eq. 22, we calculated DCp
{ of
0.6260.20 kcal/mol.K and 1.0060.42 kcal/mol.K for apo and
holo aTh, respectively. Because the heat capacity is associated to
conformational changes in the protein leading to changes in the
degree of hydration of apolar groups [43,44], we interpret the
small measured DCp
{ as indicative of only a discrete difference in
the accessible surface area between the folded and the unfolded
active state. More importantly, the DCp
{ for apo and holo aTh
are the same within error. These results indicate a similar
activation mechanism in the unfolding process between apo and
holo aTh and, consequently, that the large energetic differences
between these species reside in the decay from activated and
unfolded states.
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We have observed thermodynamic effects of ligand binding
to aT h( F i g .2 ,F i g .3a n dF i g .4 ) .U n f o r t u n a t e l y ,t h e r ei sn o
high-resolution structure of ligand-free, wild-type aTh, and
t h e r e f o r ei ti ss t i l ln o tp o s s i b l et og a i np r e c i s ei n s i g h to nt h e
structural basis of such thermodynamic behavior of aTh upon
ligand binding to the active site. Due to this lack of
structural information, we performed molecular dynamics
simulations (MD) of both aTh and aTh-PPACK to uncover
the underlying mechanism of ligand recognition and its
energetic consequences.
We observed no meaningful differences in the radius of gyration
for both aTh and aTh-PPACK throughout the simulation (data
not shown), which agrees with our SAXS measurements in
solution (Fig. 1) demonstrating that there are no or only minor
structural changes between the two species (Fig. 1). To further
monitor the conformational changes of aTh and aTh-PPACK by
MD, we separately evaluated the root mean square deviation
(RMSD) of the simulated systems using the crystallographic
structure in L-chain (Fig. 5A) and H-chain (Fig. 5B) as a reference.
Binding to PPACK resulted in increased protein rigidity with only
limited change in secondary structure (Fig. 5A and B, curves in
blue and green) and overall protein topology (Fig. 6A) from the
initial conformation.
The change in secondary structure of aTh is accompanied to
some extent by changes in the RMSD from the reference
structure, which is more pronounced in the L-chain compared
to the H-chain, as seen in Fig. 5A and 5B, respectively. Despite
the small deviation from the initial secondary structure content
we observed a high degree of fluctuation in the L-chain for both
aTh and aTh-PPACK as exhibited by the large RMSD
throughout the MD simulation trajectory, not only in secondary
structure but also in general L-chain. In opposition, the RMSD
of the H-chain occurs with only limited fluctuation throughout
the simulation (Fig. 5B), which is similar for both aTh (black
lines) and aTh-PPACK (red lines). Interestingly, under these
conditions, there is no rigidity influence of PPACK over the
aTh L-chain.
Figure 5. Overall properties assessed by MD simulations. RMSD values for free enzyme (black curve), aTh-PPACK (red curve), secondary
structure deviation in free aTh (green curve) and in complexed aTh (blue curve), for light chain (‘‘L’’, panel A) and heavy chain (‘‘H’’, panel B);
(C) H-bonds formed between coil-surrounded PPACK site in free aTh (black curve) and complexed form (red curve); (D) Total intramolecular H-bonds
formed between residues for free aTh (black curve) and complexed aTh (red curve). Details in the Experimental Methods section.
doi:10.1371/journal.pone.0024735.g005
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We can quantify the contribution of specific forces, such as
intramolecular interactions within the protein and intermolecular
interactions between the protein and the surrounding solvent. The
three aTh loops 142–153, 184–190 and 217–225 form flaps around
the active site and changes its conformation upon PPACK upon
binding (Fig. 6A). In fact, these loops surrounding the PPACK
bindingsite becomeless flexible upon ligand binding. Thisrigidityis
accompanied by an increase in both hydrogen bonds between these
loops in the vicinity of the active site (Fig. 5C) and in total
intramolecular hydrogen bonds within aTh (Fig. 5D) Additionally,
as shown in Table 2, binding to PPACK increases the interaction
energy profile between residues, which is accompanied by
a decrease in the interaction energy with the solvent, as evidenced
by the solvation enthalpy of 217,8096431 kJ/mol for aTh, and
216,6786374 kJ/mol for the aTh-PPACK complex. Free aTh
behaves differently, which explains the increased rigidity upon
PPACK binding to aTh. These data suggest that aTh becomes
more compact upon binding to PPACK, which is in consistent
with our chemical denaturation data (Fig. 3), as estimated from the
m unfolding parameter. The fact that these two unrelated ap-
proaches yield similar results validates these conclusions, providing
evidences for understanding the structural and thermodynamics
consequences of PPACK binding to aTh.
Discussion
Thrombin is a key enzyme in the coagulation cascade with
multiple allosteric behaviors. aTh activity can be regulated, both
by activation and inhibitory mechanisms, by a large class of small
and macromolecules, such as substrates, inhibitors, glycosamino-
glycans and ions [1,3]. A detailed knowledge of the precise
regulatory mechanism and ligand interaction with the active site is
highly desirable because it may support the optimization of lead
compounds in the design of direct aTh inhibitors and therefore in
the control of thrombosis and hemostasis [45,46]. PPACK is
a well-known peptide used in covalent inhibition of aTh, and the
first crystal structure of aTh was in a complex with PPACK [1,47].
Since then no comprehensive structural or thermodynamic
solution studies have been conducted with aTh. Several aspects
of aTh structure and regulation have long been addressed with the
crystallographic information gathered to date, such as interaction
with hirugen, heparin [48], and sodium ions [3], among others
compounds targeting anion-binding exosites I and II. However,
despite the large amount of structural information accumulated to
date, no high resolution solution structure has been made available
to date. The only available information in solution reveals that two
regions outside the active site undergo conformational changes
Figure 6. Superposition of unbounded aTh (salmon) and aTh-PPACK complex (blue) after 50 ns MD simulation. The loops surrounding
the PPACK binding site in the catalytic cleft are shown in detail. Both structures deviate from the original crystallographic model used in the MD
simulations (PDB ID 1PPB). Details in the Experimental Methods section.
doi:10.1371/journal.pone.0024735.g006
Table 2. Interaction energies assessed by MD for both
thrombin forms.
Interaction Energies (kJ/mol)
Intramolecular Solvent
Free aTh 13,521.996229.79 217,808.906430.83
aTh-PPACK 12,994.996209.82 216,678.056373.92
doi:10.1371/journal.pone.0024735.t002
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[38], and the NMR assignment and monitoring in changes in
aTh amide backbone due to modifications in the environment,
conformation and/or dynamic of aminoacids by the use of two-
dimensional heteronuclear correlation spectra (HSQC) [49].
Crystallization of aTh in the absence of inhibitors is limited by its
autoproteolytic cleavage in exosite I at R77a [1,3], which can be
overcome by some methods [4]. Crystal structures obtained with
inactive mutants are similar to wild-type, and in some cases
the active site is occupied by a symmetry-related enzyme [2].
A comparative analysis of the available structures deposited in the
PDB to date shows the large similarity between them, with an
overall Ca RMSD of about 1 A ˚ or less disregarding variables such
as ligands, construction/mutant, pH, and solvent conditions [50].
This limited variability may be attributed to the inherent lack of
structural diversity, discret ligand influence over aTh structure or
even the limitations of the crystallographic method due to the solid,
crystal phase condition in which the structure is solved, and also due
to conformational restriction imposed by crystal packing with
symmetry related aTh neighbors as previously suggested [21].
Our SAXS results indicate that both apo and PPACK-bound
forms of aTh share a similar overall shape in solution. In fact,
crystallographic structures of wild-type aTh in complex with
PPACK (PDB entries 1PPB, 1SHH, 1SFQ; [1,3]), in the free form
(PDB entry 2AFQ [4]) or aTh mutants in the absence of ligands
(PDB entries 2GP9, 1SGI, 1SG8; [3,51] share large similarity
among them (RMSD for Ca,0.8 A ˚), and their local differences in
some regions are not detectable by SAXS measurement due to the
inherent limited resolution. In opposition, circular dichroism
spectra indicates that aTh is a highly variable protein, with
a responsive structure upon ligand recognition and solution
conditions such as pH, cation, heparin and other ligands
[52–54]. In fact, aTh in solution display a dissimilar conformation
compared to its crystal structure, as revealed by molecular
dynamic simulation [21].
Despite the similarity in the overall three-dimensional solution
structure of apo and holo aTh as assessed by SAXS (Fig. 1), other
approaches revealed remarkable differences between them, such
as changes in secondary structure as judged by CD (Fig. 2A)
accompanying structural rearrangement, leading to the increase in
thermodynamic stability as measured by heat and GdmCl induced
unfolding (Fig. 2 and 3), and the drift in some loops from initial
crystallographic conformations after MD simulation (Fig. 6).
Moreover, we have observed a complex modulation of aTh
upon interaction with PPACK. In addition to the gain in stability
against heat and GdmCl denaturation, an equilibrium interme-
diate between native and denaturant-induced unfolded aTh is
populated. The chemical denaturation pathway of aTh, as shown
here using GdmCl as denaturant, reveals the accumulation of an
intermediate conformational state with increased catalytic activity,
which has been previously shown by our group in urea-induced
denaturation assays [8].
In the kinetic refolding/unfolding process a kinetic intermediate
is also observed, which closely correlates with the equilibrium
intermediate as shown in the Chevron plot (Fig. 4F). A thermody-
namic change in protein stability does not rise solely from punctual
interaction between the ligand (i.e., PPACK) and the enzyme
(aTh). Instead, changes in intramolecular interaction are likely to
take place and, consequently, conformational changes in both
secondary and tertiary structure may occur upon ligand binding.
Interestingly, stopped-flow measurements demonstrated that
both aTh forms behaves similarly in the kinetic refolding step, and
differing in the kinetic unfolding step. We speculate that these
differences in unfolding kinetics arise from differences in the
consolidated, folded conformation of apo and holo aTh, indicating
that PPACK binding leads aTh to a dissimilar conformational
state from apo aTh, also supported by the changes in overall
secondary structure content (Fig. 2A). These conclusions are not
conflicting with our SAXS data, since scattering is a low-resolution
technique (in this case, resolution is of about 2p/qmax=30A ˚), and
therefore cannot provide details of secondary structure elements,
giving insight only on particle properties such as Rg and Dmax.
MD techniques have been used to provide insights into the
molecular basis of interaction between aTh and ligands such as
DNA aptamer [55], suramin [21], heparin, thrombomodulin and
Factor XIII Activation Peptide [56]. In fact, MD coupled with
thermodynamic measurements from solution provides a direct
access to novel aspects of protein interaction, in the energetic of
binding and conformational changes upon recognition.
At the atomic scale, MD simulations also agree with the
hypothesis of distinct conformational states between the two aTh
forms, suggesting that PPACK binding is able to promote
a reorientation of enzyme loops, mainly those surrounding the
enzyme active site, promoting an increase in the overall protein
rigidity and a lowering in its exposure to solvent, thus resulting in
increased thermo stability of the enzyme. No major modifications
in Rg and secondary structure elements were observed in the time
scale of the simulations performed.
Our data provide evidences that aTh and aTh-PPACK display
dissimilar conformations, especially when compared to the
crystallographic free (both S195A and R77aA mutants and wild-
type forms) and PPACK-bound forms of aTh. In addition, we
show an intermediate state of aTh, which is found both in
equilibrium and in the kinetic refolding/unfolding pathways. This
novel intermediate species of aTh correlates with increased
activity [8], and it is likely to possess a less rigid conformation
compared to both aTh and aTh-PPACK due to the elevated
concentration of denaturant when it is accumulated in equilibri-
um, which in the end suggests an inverse correlation between aTh
rigidity and activity.
The design of drugs based on high-resolution structures of
protein has a successful history in therapeutic classes such as in the
case of HIV, nuclear receptors and NSAID. Most active site direct
inhibitors were developed based on the described aTh-PPACK
complex [5,57]. Despite of the wealth of structural information
since the elucidation of the aTh crystal structure [1,3], approval of
direct thrombin inhibitors for clinical use is very recent. The lack
of a close similarity between aTh structure in crystal and solution
phases may be a primary cause of delay in drug development in
this field, as evidenced by the development of such inhibitors based
on classical medicinal chemistry [5]. aTh was considered to be
a rigid molecule with restricted conformational change [5,58]. In
contrast, we have shown a highly dynamic enzyme with
a multiplicity of conformations, a common feature in biological
systems with seminal importance in drug design [59].
Crystallography has long been a valuable tool in the
understanding of structural principles of molecular recognition
and function. We believe that the combined use of crystallographic
methods as currently used in structural genomic and molecular
dynamics database initiatives [60,61], with solution studies by
means of molecular dynamic simulation and the advance in the
NMR characterization of aTh [49], will provide further advances
in the understanding of protein function and the structure-activity
relationship of aTh.
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